Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$372K Buy
1,193
+179
+18% +$52.9K 0.02% 151
2024
Q4
$264K Sell
1,014
-70
-6% -$20.8K 0.02% 189
2024
Q3
$349K Sell
1,084
-35
-3% -$11.4K 0.02% 155
2024
Q2
$350K Buy
1,119
+353
+46% +$104K 0.03% 145
2024
Q1
$218K Sell
766
-4
-0.5% -$1.17K 0.02% 181
2023
Q4
$222K Buy
+770
New +$210K 0.02% 174
2023
Q1
Sell
-1,007
Closed -$265K 163
2022
Q4
$265K Buy
+1,007
New +$270K 0.03% 137
2021
Q3
Sell
-1,053
Closed -$257K 145
2021
Q2
$257K Buy
1,053
+36
+4% +$8.86K 0.06% 122
2021
Q1
$253K Buy
+1,017
New +$243K 0.11% 103
2020
Q4
Sell
-881
Closed -$224K 82
2020
Q3
$224K Sell
881
-29
-3% -$7.18K 0.18% 76
2020
Q2
$215K Buy
+910
New +$208K 0.22% 66

Other funds holding AMGN

Adero Partners's AMGN Position: Q1 2025 in Review

Adero Partners increased its Amgen (AMGN) stake by 18% in Q1 2025, buying an estimated $52.9K and bringing the position to 1,193 shares worth $372K. The position accounts for 0.02% of the portfolio, ranked #151.

Adero Partners first reported a position in AMGN in Q2 2020 and has held it in 11 quarters since. 2,927 funds tracked by Wall St. Rank hold AMGN as of Q1 2025.

  • Adero Partners held 1,193 shares of Amgen worth $372K as of Q1 2025.
  • Adero Partners bought 179 Amgen shares in Q1 2025, an estimated $52.9K.
  • Amgen made up 0.02% of Adero Partners's portfolio in Q1 2025, its #151 holding.
  • Adero Partners first reported a position in Amgen in Q2 2020 and has held it in 11 quarters since.
  • 2,927 funds tracked by Wall St. Rank held Amgen as of Q1 2025.

Based on Adero Partners's 13F filing for Q1 2025, filed 17 Apr 2025.